Skip to main content
    P

    PTC Therapeutics Inc (PTCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $63.49
    +0.13 (+0.21%)

    Market Cap: $5.30B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    PTC Therapeutics Inc (PTCT) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to PTC Therapeutics are Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX) and Travere Therapeutics (TVTX). By market cap, PTC Therapeutics ranks 5th of the 13 companies on this page; TG Therapeutics (TGTX) is the largest at $9.75B. The median P/E of the 4 companies with a P/E is 63.8x.

    Peer Comparison

    PTCT's ROIC of 18.1% is above the peer median of -26.4%, and its revenue growth of 69.6% is above the median of 48.5%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    PTC Therapeutics (PTCT)$5.30BN/A5.2x-9.2%18.1%69.6%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    TG Therapeutics Inc (TGTX)$9.75B87.2x11.1x11.8%11.0%60.7%0.00%
    Travere Therapeutics Inc (TVTX)$4.86BN/A7.2x-18.7%-23.1%36.2%0.00%
    Cogent Biosciences Inc (COGT)$4.97BN/AN/A0.0%-43.4%-100.0%0.00%
    Praxis Precision Medicines Inc (PRAX)$9.17BN/AN/A0.0%N/A1349.0%0.00%
    Crispr Therapeutics AG (CRSP)$4.10BN/A155.2x0.0%-20.3%1325.0%0.00%
    Tarsus Pharmaceuticals Inc (TARS)$3.96BN/A5.4x-102.9%-393.6%63.9%0.00%
    Dianthus Therapeutics Inc. (DNTH)$5.17BN/AN/A0.0%N/A205.6%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Krystal Biotech Inc (KRYS)$9.05B40.4x18.8x47.9%N/A30.2%0.00%
    Palvella Therapeutics, Inc (PVLA)$2.23BN/AN/A0.0%N/A0.0%0.00%
    Legend Biotech Corp (LEGN)$3.39B266.5x2.3x-0.0%N/A32.0%0.00%
    Peer median$4.92B63.8x13.0x0.0%-26.4%48.5%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to PTC Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors
    TG Therapeutics Inc (TGTX)
    TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development...
    TGTX competitors
    Travere Therapeutics Inc (TVTX)
    Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification...
    TVTX competitors
    Cogent Biosciences Inc (COGT)
    Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases.
    COGT competitors
    Praxis Precision Medicines Inc (PRAX)
    Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal...
    PRAX competitors
    Crispr Therapeutics AG (CRSP)
    CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases.
    CRSP competitors
    Tarsus Pharmaceuticals Inc (TARS)
    Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates...
    TARS competitors
    Dianthus Therapeutics Inc. (DNTH)
    Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops...
    DNTH competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Krystal Biotech Inc (KRYS)
    Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United...
    KRYS competitors
    Palvella Therapeutics, Inc (PVLA)
    Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from...
    PVLA competitors
    Legend Biotech Corp (LEGN)
    Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology...
    LEGN competitors

    Frequently Asked Questions About PTCT

    Who are PTC Therapeutics' main competitors?

    The companies most similar to PTC Therapeutics include Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX), Travere Therapeutics (TVTX), Cogent Biosciences (COGT) and Praxis Precision Medicines (PRAX), listed from the closest match.

    Who is PTC Therapeutics' biggest competitor?

    TG Therapeutics (TGTX) is the largest of the similar companies at $9.75B; Protagonist Therapeutics (PTGX) is the closest match by business profile, size, sector and industry.

    How does PTCT stock compare with its competitors?

    PTCT's P/S is 5.2x against a peer median of 13.0x; its net margin is -9.2% against a peer median of 0.0%.

    Which of PTC Therapeutics' competitors pays a higher dividend?

    PTC Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is PTC Therapeutics bigger than its competitors?

    No. PTC Therapeutics is 5th by market cap among the 13 companies on this page; the largest is TG Therapeutics (TGTX) at $9.75B.